ITOS实时信号 | 通过Getagraph.com最大化利润

出售 106864 min ago

@ $10.28

发出时间: 14 Feb 2024 @ 22:30

回报率: 5.06%

上一信号: Feb 13 - 04:25

上一信号: 购买

回报率: -3.95 %

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients...

Stats
今日成交量	135 657
平均成交量	277 176
市值	387.11M
EPS	$0 ( 2024-03-20 )
下一个收益日期	( $-1.020 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.43
ATR14	$0.0140 (0.13%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-07	Gall Matthew	Buy	163 200	Stock Option (Right to Buy)
2024-03-07	Call Matthew	Buy	225 000	Stock Option (Right to Buy)
2024-03-07	Mcgrath Yvonne	Buy	153 600	Stock Option (Right to Buy)
2024-03-07	Detheux Michel	Buy	590 400	Stock Option (Right to Buy)
2024-03-07	Desimone Jill	Buy	44 766	Stock Option (Right to Buy)

INSIDER POWER
64.32
Last 98 transactions
Buy: 4 056 310 \| Sell: 3 240 538

音量相关性

長: -0.05 (neutral)

短: 0.71 (moderate)

Signal:(45.154) Neutral

iTeos Therapeutics, Inc. 相关性

10 最正相关
VERU	0.964
AADI	0.945
MDRX	0.944
TWST	0.941
SGMO	0.941
LSBK	0.939
BLNK	0.936
ACRS	0.936
AKTX	0.936
ALHC	0.936

10 最负相关
CPTA	-0.934
RAM	-0.928
SGEN	-0.924
TYHT	-0.916
GPACU	-0.906
DRNA	-0.902
PESI	-0.897
XPON	-0.891
AMPH	-0.886
MLAI	-0.886

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

iTeos Therapeutics, Inc. 相关性 - 货币/商品

-0.45
( neutral )

-0.32
( neutral )

0.00
( neutral )

-0.54
( weak negative )

0.00
( neutral )

0.34
( neutral )

iTeos Therapeutics, Inc. 财务报表

Annual	2023
营收:	$12.60M
毛利润:	$11.70M (92.87 %)
EPS:	$-3.15

FY	2023
营收:	$12.60M
毛利润:	$11.70M (92.87 %)
EPS:	$-3.15

FY	2022
营收:	$267.63M
毛利润:	$266.82M (99.70 %)
EPS:	$2.72

FY	2021
营收:	$344 775
毛利润:	$344 775 (100.00 %)
EPS:	$0.00881

Financial Reports:

No articles found.

iTeos Therapeutics, Inc.

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.